Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Tumoricidal activity of human dendritic cells

Jurjen Tel1*, Sébastien Anguille2*, Claire E.J. Waterborg1, Evelien L. Smits3,4, Carl G. Figdor1, and I. Jolanda M. de Vries1,2

1Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
2Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
3Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
4Center for Oncological Research, University of Antwerp, Antwerp, Belgium

Dendritic cells (DCs) are a family of professional antigen-presenting cells (APCs) that are able to initiate innate and adaptive immune responses against pathogens and tumor cells. The DC family is heterogeneous and is classically divided into two main subsets, each with its unique phenotypic and functional characteristics: myeloid DCs (mDCs) and plasmacytoid DCs (pDCs). Recent results have provided intriguing evidence that both DC subsets can also function as direct cytotoxic effector cells; in particular, against cancer cells. In this review, we delve into this understudied function of human DCs and discuss why these so-called killer DCs might become important tools in future cancer immunotherapies.

DCs: commanders-in-chief of the immune army

Forty years after their discovery by Zanvil Cohn and Ralph Steinman, DCs continue to fascinate and intrigue immunologists. Although the nomenclature of the DC system is still evolving and novel markers to identify and subclassify DCs are being continually identified, it is well established that the DC family constitutes a heterogeneous group of cells that can be categorized in two main subtypes: mDCs and pDCs. Despite the considerable heterogeneity between the different DC types in terms of phenotype, gene expression profile, and function, a common characteristic of all DCs is their capacity for antigen presentation and their unique ability to prime and activate naive T lymphocytes. As the primary APCs of the immune system, DCs are pivotal in eliciting adaptive immune responses and, as such, in determining the balance between immunity and tolerance [1]. In addition to their central role in adaptive immunity, DCs also occupy a pre-eminent place within the innate immune system. In this context, DCs express Toll-like receptors (TLRs); a family of innate immune receptors involved in sensing viruses and other microbial stimuli. DCs are also capable of activating other innate immune cells, including natural killer (NK) cells.

Given their key role in regulating innate and adaptive immunity, DCs are critical for the induction of antitumor immunity [1]. Through their role in the induction of antigen-specific cytotoxic T lymphocytes (CTLs) and through their capacity to harness the cytotoxic activity of innate immune cells (NK cells, NKT cells, and γδ T cells), DCs can elicit potent cytotoxic immune responses towards tumor cells [2]. Evidence from animal and human studies indicates that DCs themselves can initiate cytotoxic effector function through which they directly contribute to tumor cell killing. These so-called killer DCs were first described in the mid-1990s, when a population of murine DCs was identified with the capacity to lyse CD4+ T cells in a FAS–FAS ligand (FAS-L)-dependent fashion [3]. Almost one decade later, three research groups independently reported on the existence of a novel DC type within the murine immune system that bore phenotypic, molecular, and functional characteristics of both DCs and NK cells [4–6]. This DC subtype was termed natural killer dendritic cell (NKDC) or, alternatively, interferon-producing killer DC (IKDC) [4] because of its NK cell-like properties such as cytotoxic activity and capacity to produce high amounts of interferon (IFN)-γ [4–6]. Although NKDCs were capable of antigen processing and presentation, it soon became apparent that this term was actually a misnomer because NKDCs belong to the NK cell lineage and not to the DC lineage [7–9]. This apparently erroneous terminology has led to confusion and even skepticism over the actual existence of killer DCs.

Recent studies, however, have provided substantial evidence for direct cytotoxic effector function in DCs. These killer DCs, which have been identified in both rodents and humans, appear to constitute a heterogeneous population of cells that have the following characteristics in common: (i) they are endowed with direct cytolytic potential; (ii) they fulfill the phenotypic and functional criteria to be classified as bona fide DCs; and (iii) they cannot be defined as NK cells despite their cytotoxic activity (e.g., absence of classical NK cell surface markers, and target cell profile different from that of NK cells). Here, we summarize the findings accumulated in recent years on killer DCs and discuss the potential relevance of these cells to future immunotherapy.

**Keywords:** plasmacytoid dendritic cells; myeloid dendritic cells; cytotoxicity; TRAIL; granzyme B; antitumor therapy.

*These authors contributed equally to this work.

1471-4906/$ – see front matter
© 2013 Elsevier Ltd. All rights reserved. http://dx.doi.org/10.1016/j.it.2013.10.007
tumor-selective action remain incompletely understood, although the expression of decoy receptors (e.g., TRAIL death receptor DR1 and DR2) and the activation of antiapoptotic mechanisms (e.g., upregulation of cellular FADD-like IL-18-converting enzyme protease-inhibitory protein (c-FLIP)) may help to explain why normal cells are largely resistant to killing by MoDCs [25].

Despite their seemingly preferential tumor-directed action, under certain circumstances, MoDCs can induce T cell death [21,32,37]. This observation was made in several studies (Table 1); all of which were performed in the context of infectious diseases [21,32,37]. The first study demonstrated that MoDCs infected with measles virus can induce paracrine killing of autologous T cells [19]. Monocytes [38] and MoDCs [21] exposed to HIV-1 were capable of inducing apoptosis of HIV-1-infected as well as noninfected CD4+ T cells from either allogeneic or autologous origin. In another study, it was shown that LPS-matured MoDCs derived from tuberculosis patients had an increased expression of PD-L1, which underlined their antiproliferative and proapoptotic activity towards both CD4+ and CD8+ T cells [37]. Similarly, LPS-matured MoDCs generated from chronic hepatitis C patients were found to lyse both healthy (allogeneic) as well as patient-derived (autologous) CD4+ T cells in a PD-L2- and FAS-L-dependent fashion [32]. Taken together, these findings indicate that human monocytes and MoDCs, when appropriately stimulated, can function as cytotoxic antitumor effectors and, in the context of chronic infection, also as immunoregulatory cells with T cell killing activity.

Blood mDCs as killer cells

Although the observation that ex vivo generated MoDCs can act as direct killer cells is interesting, another relevant question is whether this is also applicable to naturally circulating DCs. Although most studies used MoDCs, several studies have delved into the killer function of blood DCs and have shown that the two main blood DC subsets, mDCs and pDCs, can be cytotoxic. The human blood mDC subset is usually defined as lineage (Lin)-HLA-DR+CD11c+CD123+IL-3Rα+dim cells. Blood mDCs can be further subdivided in nonoverlapping subsets based on the expression of blood dendritic cell antigen (BDCA)-1 (CD1c) and BDCA-3 (CD141) [39]. Classically, mDCs remain in an immature state and migrate from peripheral tissues to lymph nodes after maturation where they can activate T cells. Cytotoxic potential has hitherto been reported for the total CD11c+ mDC population, as well as for the CD1c+ subset (Table 2). The first description of the direct cytotoxic activity of human blood mDCs dates back to the late 1990s, where CD11c+ mDCs, stimulated with IFNα or IFNγ, directly lysed various tumor cell lines in a TRAIL-dependent fashion [40]. TRAIL has also been implicated in blood DC-mediated cytotoxicity in two other studies [41,42] (Table 2). By contrast, TRAIL seems not to be an important mediator of cytotoxicity by TLR-activated mDCs. A recent study showed that neither BDCA-1- nor BDCA-3- mDCs produce TRAIL after exposure to TLR ligands [43]. In line with this, it was observed that tumor-infiltrating CD11c+ mDCs express and secrete perforin and granzyme B, but not TRAIL, upon TLR7 and TLR8 stimulation [44].
| Cell type      | Stimulation       | Target                          | E:T ratio | Killing mechanism            | Refs |
|---------------|-------------------|---------------------------------|-----------|-----------------------------|------|
| Monocytes     | HIV-1             | T cells                         | 1:1       | Contact dependent           | [38] |
| Monocytes     | IFNγ, IFNγ        | OVCAR3 (ovarian cancer) WM793 (melanoma) MDA231 (breast cancer) Colo205 (colon cancer) PC-3 (prostate cancer) H2126 (lung cancer) | 50:1     | TRAIL                       | [12] |
| Monocytes     | IFNγ              | HSC3 (oral squamous cell carcinoma) | 50:1     | TWEAK, TRAIL                | [15] |
| Monocytes     | LPS               | K562 (leukemia)                 | 10:1      | No involvement of Fas-L, TNF-α or TGF-β | [14] |
| Monocytes     | IFNα              | K562 PC-3 Jurkat (T cell leukemia) | ?         | TRAIL²                      | [13] |
| CD16⁺ slan DCs| Unstimulated      | Colo205 SkBr3                   | 40:1      | ADCC by 17-1A (colo205) or herceptin (SkBr3) Effector molecule: TNF-α | [17] |
| CD16⁺ slan DCs| M-DC8⁺            | IFN-γ                           | 40:1      | ND                          | [16] |
| CD16⁺ slan DCs| (CHC)             | IMQ or resiquimod              | 40:1      | ND                          | [77] |
| MoDCs (measles)| Measles virus     | MDA231                          | 50:1      | TRAIL                       | [18] |
| MoDCs         | LPS               | Jurkat Molt (T cell leukemia) K562 THP-1 (monocytic cancer) U937 (lymphoma) | 1:1       | Contact dependent           | [78] |
| MoDCs         | Measles virus     | MDA231                          | 50:1      | TRAIL                       | [18] |
| MoDCs         | Immature          | OVA.1 (ovarian cancer) SW626 (ovarian cancer) | 40:1     | FAS-L                       | [31] |
| MoDCs         | Immature          | SiHa, Caski (HPV+ cervical cancer) | 8:1      | Contact-dependent no involvement of TRAIL or FAS-L | [79] |
| MoDCs         | CD14⁺, CD34⁺      | IFNβ                            | 20:1      | TRAIL²                      | [25] |
| MoDCs         | dsRNA → CD40L →   | MDA231                          | 50:1      | TRAIL²                      | [24] |
| MoDCs         | CMV               | CMV-reactive T cells            | 1:5:3     | FAS-L, TRAIL                | [20] |
| MoDCs         | Immature          | Jurkat Molt MCF-7 (breast cancer) U87 (glioblastoma) HCT-5 (colorectal cancer) A498 (renal cancer) 786.O (renal cancer) Caki.2 (renal cancer) | 10:1     | Caspase 8 (FADD independent) | [33] |
| MoDCs         | CD40L             | PCI-13 SSCHN (head and neck cancer) | 1:1      | TNF-α, LT-α, LT-β, FAS-L, TRAIL² | [29] |
| MoDCs         | CD40L, LPS        | MCF-7 MDA-MB-468 (breast cancer) SK-BR-3 (breast cancer) | ?        | TNF-α² Contact independent | [30] |
| MoDCs         | HIV-1 IFNα        | MDA231 CD4⁺ T cell line HIV-H9 CD4⁺ T cells (HIV-1 viremic patients) | ?        | TRAIL², FAS-L², TNF-α² TWEAK² | [21] |
| MoDCs         | HIV-1 (nef)       | CD8⁺ T cells                    | ?        | sTNF-α FAS-L                | [22] |
| MoDCs         | Immature          | Jurkat                          | 10:1      | Caspase 8/Bcl-2 (FADD independent) | [35] |
| Cordblood MoDCs| IFNγ, LPS         | HL60, Jurkat Daudi, Jurkat      | 20:1      | ND                          | [80] |
| MoDCs         | IFNα              | K562                            | 20:1      | ND                          | [81] |
| MoDCs         | HIV-1 (Vpr) + LPS | Allogeneic CD8⁺ T cells          | 1:20      | sTNF-α                    | [23] |
| MoDCs         | HIV-1 (Vpr) + LPS | U251 (glioma) Jurkat            | 20:1      | Contact dependent FADD and caspase-8 dependent | [34] |
Table 1 (Continued)

| Cell type | Stimulation | Target | E:T ratio | Killing mechanism | Refs |
|-----------|-------------|--------|-----------|-------------------|------|
| MoDCs     | IFNα        | K562   | 50:1      | TRAIL*            | [26] |
| MoDCs     | OK432       | T2 K562 EJ 253J | 10:1 | Contact dependent (CD40–CD40L) | [82] |
| MoDCs     | Immature (CD123*) | U937 Jurkat HL-60 | 40:1 | TRAIL | [83] |
| MoDCs     | CD40L       | OSC-70 (oral squamous cell carcinoma) | 1:8 | TRAIL* IFN-γ | [28] |
| MoDCs     | SARS coronavirus | ND | ND | TRAIL | [84] |
| MoDCs     | LPS         | SkBr3 (Her-2-neu+ breast cancer) | 100:1 | ADCC by trastuzumab | [85] |
| MoDCs     | LPS         | MCF7 (breast) HeLa (cervix) HT29, HCT116, SW480 (colorectal) no killing of T lymphocytes | 5:1 | peroxynitrites | [86] |
| MoDCs     | IFNα, LPS   | CD4+ T cells CD8+ T cells | 10:1 | PD-L1 | [37] |
| MoDCs     | IFNγ, LPS   | T47D (breast cancer) | ND | ND | [87] |
| MoDCs     | IL-15       | K562   | 50:1      | Granzyme B, TRAIL* | [27] |
| MoDCs     | (CHC patients)* | LPS | Allogeneic healthy CD4+ T cells Autologous CD4+ T cells | 4:1 | FAS-L, PD-L2, Contact dependent | [32] |
| MoDCs     | γ-irradiated HT-29 | HT-29 (colon cancer) | 20:1 | Perforin/granzyme B | [36] |

*Partially dependent, other mechanisms (shown when possible) may be involved.
*Chronic hepatitis C patients.
Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; CB, cord blood; E: T ratio, effector cell to target cell ratio; FADD, FAS-associated protein with death domain; HPV, human papillomavirus; ND, not determined; PB, peripheral blood; TGF, transforming growth factor.

Granzyme B has also been implicated in mDC-mediated apoptosis in IL-15-activated CD11c+ mDCs [45]. Taken together, these data illustrate that killer mDCs, like their in vitro MoDC counterparts, can exploit a variety of cytotoxic effector mechanisms to exert killing function (Table 2). Similar to MoDCs, most studies on the killer function of native blood mDCs have been performed using tumor cell lines as target cells. The ability of blood mDCs to kill T cells was examined in one study that showed LPS-activated BDCA-1+ mDCs from chronic hepatitis C patients induced lysis of autologous patient T cells as well as allogeneic healthy T cells in a FAS-L- and PD-L2-dependent fashion (Table 2) [32]. This study provides evidence for the ability of native blood mDCs to kill T cells during chronic viral infection, a mechanism that may be exploited by viruses to escape antiviral T cells.

**pDCs as killer cells**

pDCs are defined as Lin−D11c−CD4+CD45RA−IL-3Rα−C–D123−ILT3− cells. Additionally, the markers BDCA-2 (CD303), BDCA-4 (CD304), and immunoglobulin-like transcript (ILT)7 are restricted to pDCs both in peripheral blood and bone marrow [46]. On the functional level, human pDCs differ from other DC subsets by their ability to produce large amounts of type I IFNs upon TLR7 or TLR9 ligation by viral or bacterial components [47]. pDCs are generally found to circulate in the periphery, however they can infiltrate tissue in case of infection, inflammation, or tumor [44,48]. Like their myeloid counterparts, pDCs are also described to exert a direct cytotoxic function (Figure 1 and Table 2). For example, the human pDC cell line GEN2.2 is capable of lysing tumor cells in a partly TRAIL-dependent manner after stimulation with inactivated influenza virus or type I IFNs (Table 2). This pDC cell line expresses the NK cell surface marked CD56, whereas other NK cell markers are absent [49]. pDCs activated by the tick-borne encephalitis vaccine FMSE also upregulate CD56, whereas IL-3 or several TLR agonists do not induce upregulation [50]. The CD56+ pDCs express high amounts of TRAIL and granzyme B but neither the cytotoxic molecules nor CD56 are required for the observed cytotoxicity. Nevertheless, the killing capacity is dependent on cell-to-cell contact, whereby FSME-pDCs specifically lyse MHC-class-I-negative tumor cell lines Daudi and K562, but not MHC class I positive cell lines [50]. By contrast, pDCs stimulated with imiquimod (a TLR7 agonist and to lesser extend TLR8 agonist), CpG, or IFN-α kill MHC-class-I-positive tumor cells in a TRAIL- and contact-dependent manner [44,51]. Although TRAIL appears to be an important mediator of pDC-mediated cytotoxicity, other cytotoxic effector molecules are implicated (Table 2). It has been shown that different cytotoxic effector molecules are expressed by blood pDCs, including TRAIL, granzyme B, and lysozyme. High lysozyme expression by the CD2high pDC subset has been observed, although this is not related to the increased cytotoxic activity of the CD2high pDCs as compared to their CD2low counterparts. It is important to note that the high lysozyme expression in the CD2high pDC subset could not be confirmed in another independently performed study [51], indicating that other mechanisms, such as the superior ability of...
Table 2. Human killer DCs divided into major subsets

| Subset of DC | Stimulation | Target | E:T ratio | Killing mechanism | Refs |
|--------------|-------------|--------|-----------|------------------|------|
| mDCs         | IFNα, IFNγ | Jurkat | 50:1      | TRAIL            | [40] |
| CD11c⁺ blood mDCs | IFN-γ, IL-15, LPS | MCF-7 | 10:1 | ND               | [88] |
| CD11c⁺ mDCs   | IMQ         | K562   | 25:1      | Perforin/granzyme B | [44] |
| CD1c⁺ mDCs (CHC patients) | Unstimulated | K562 | 50:1 | TRAIL          | [42] |
| Blood mDCs    | IL-15       | Human aortic endothelial cells | 10:1 | Granzyme B / caspase 8 | [45] |
| BDCA-1⁺       | LPS         | Allogeneic healthy CD4⁺ T cells | 4:1 | FAS-L/ PD-L2/ Contact dependent | [32] |

| pDCs          |                          |        |           |         |      |
|---------------|--------------------------|--------|-----------|---------|------|
| pDC cell line GEN2.2 Blood pDCs → | Influenza virus, Type I IFNs | A549 (epithelial cancer) | 25:1 | TRAIL⁺ | [49] |
| Blood pDCs    | IMQ                      | Jurkat | 15:1      | TRAIL  | [44] |
| Blood pDCs    | HIV-1                    | SupT1 (CD4⁺ T cell line) | 20:1 | TRAIL⁺ | [56] |
| Blood pDCs    | HIV-1                    | CD4⁺ T cells (HIV-1 viremic patients) | 10:1 | TRAIL IFNα | [89] |
| Blood pDCs    | IL-3/CD40L → Cpg →       | K562   | 100:1     | Contact dependent | [52] |
| Blood pDCs    | Flu Cpg                  | Jurkat J32 | Culture Sup | TRAIL | [90] |
| Blood pDCs    | HTLV-1                   | DR5⁺ T cells | 1:2 | TRAIL | [55] |
| Blood pDCs    | HIV                      | HIV-infected Sup-T cell line | 10:1 | TRAIL | [58] |
| Blood pDCs    | IL-3/IL-10               | T cells | 1:250 | Granzyme B | [54] |
| Blood pDCs    | IL-3                     | K562   | 10:1      | Granzyme B / Caspase | [53] |
| Blood pDCs    | CpG                      | H8 (CD4⁺ T cell line) | 2:1 | TRAIL⁺ | [57] |
| Blood pDCs    | IMQ Cpg IFNα             | Jurkat WM793 SKMel2 (melanoma) | 20:1 | TRAIL | [51] |
| Blood pDCs    | IL-3 → R848 → FSME →     | K562   | 20:1      | ND      | [50] |

*Partialy dependent, other mechanisms (shown when possible) may be involved.

bChronic hepatitis C patients.

Abbreviation: IMQ, imiquimod.

CD2high pDCs over CD2low pDCs to bind their targets, might be involved in the cytotoxic action of CD2high pDCs [52]. Expression of granzyme B has been observed in unstimulated pDCs [51,52] as well as in pDCs stimulated with IL-3 and/or IL-10 [50,53,54], but this molecule only seems to contribute to cytotoxicity in the stimulated pDCs. These granzyme-B-producing, IL-3- and IL-10-activated pDCs are known to be cytotoxic to target T cells in a granzyme-B-dependent, but perforin-independent manner [54]. This confirms the findings by others that killer DCs can mediate cytotoxicity through the granzyme pathway while being completely devoid of perforin [27,51]. Apart from granzyme B, TRAIL has also been implicated as a mediator of T cell lysis by pDCs. pDCs stimulated with purified human T cell leukemia virus (HTLV)-1 or HIV-1 upregulate TRAIL and induced TRAIL-dependent apoptosis in primary CD4⁺ T cells or CD4⁺ T cell lines [55,56]. Both the TLR7 pathway and endosomal degradation are involved in the transformation of pDCs into their killer variant by HLTV-1 [55]. In agreement with this, pDCs isolated from viremic HIV-infected CD4⁺ T cells express TRAIL and induce apoptosis of HIV-infected CD4⁺ T cells [57]. In another study, TRAIL⁺ pDCs

42
displayed no cytotoxic responsiveness to HIV-infected autologous CD4+ T cells, but were capable of inducing apoptosis of an HIV-infected CD4+ T cell line [58]. The ability of human killer pDCs to induce apoptosis in virus-infected cells may be a protective mechanism by which the host immune system controls virus spread [59].

**Killer DCs in the war on cancer**

**Indirect cytotoxic effects of pDC-derived type I IFNs**

pDCs are generally accepted as the major type I IFN-producing cells of the immune system. These type I IFNs can initiate protective immunity through maturation of mDCs and subsequent activation of T cells and NK cells (reviewed in [60]). Thereby, pDCs may play a central role in inducing indirect cytotoxic activity against tumors via various pathways, for example, apoptosis induction and anti-angiogenesis via signaling through a common IFNα receptor. Furthermore, the direct inhibitory effects on tumor cell growth/functions were thought to be the major mechanisms in the antitumor response in IFN-treated patients. In fact, IFNα can directly inhibit the proliferation of tumor cells both in vitro and in vivo, and can exert other direct effects on tumor cells (Figure 2) [61]. Next to a direct cytotoxic and cytostatic effect, IFNα also has wide stimulatory effects on other immune cells. As discussed above, monocytes can differentiate into killer DCs under the control of IFNα. In addition, recent studies have shown that IFNα also improves mDC survival and the capacity to store and process exogenous antigens, leading to enhanced cross-presentation and cross-priming of antigen-specific CD8+ T cell responses [62,63]. In vivo evidence was recently provided by two independent studies showing that, in mice, type I IFNs were critical for the induction of antitumor immune responses [62,64]. Furthermore, type I IFNs can regulate NK cell function, by enhancing the NFκB activity of NK cells to kill target cells and to produce IFNγ [65]. Also, type I IFNs promote the accumulation and/or survival of proliferating NK cells by the type I IFN and signal transducer and activator of transcription (STAT)1-dependent induction of IL-15 [65].

These studies suggest that upon activation, pDCs can exert a wide variety of indirect cytotoxic antitumor effects (Figure 2). This notion is underscored by a study demonstrating that either pDC or IFNα depletion leads to a loss of the TRAIL-mediated tumor cell killing by CD14+ monocytes. This highlights a crucial role for pDC-derived IFNα in antitumor immunity [66]. The expression of TRAIL on a wide variety of immune cells is known to be regulated by type I IFNs [67,68]. Moreover, in some studies there has even been a direct link between pDC-derived type IFN, TRAIL expression, and target killing in the context of HIV [57,69]. Whether or not killer pDCs also acquire TRAIL expression under all other reported conditions in a para-
crine or autocrine type-I-IFN-dependent manner remains to be determined.

**Activation of tumor-infiltrating DCs to boost antitumor immunotherapy**

The discovery of the ability of DCs to become tumor cell killers has generated new opportunities for future nonconventional immunotherapeutic strategies. It is generally accepted that macrophages and DCs outnumber NK cells and CTLs in tumor tissues, making these professional APCs ideal candidates to target and induce an antitumor response [10]. Human DCs infiltrate a vast range of tumors including skin cancer, ovarian carcinoma, and lung and colorectal cancer. However, this infiltration does not lead to a conclusive role in prognosis [48]. Infiltration by pDCs in breast cancer and ovarian carcinoma is correlated with an adverse prognostic outcome [70,71], whereas infiltration of pDCs in lung cancer does not correlate with prognosis [72]. In particular, a tolerogenic state seems to be of importance because DCs can remain in an inactivated state due to the immunosuppressive environment of the tumor [48].

Nevertheless, some studies have shown tumor regression upon treatment with several TLR agonists, such as CpG or imiquimod. Stary et al. have shown that, upon treatment of basal cell carcinoma patients with imiquimod, mDCs and pDCs are recruited to the tumor site and express cytotoxic effector molecules [44]. In a mouse model of transplantable melanoma, treatment with imiquimod led to tumor clearance in a manner dependent on production of chemokine CC ligand (CCL)2 by mast cells. CCL2 induced the massive recruitment of pDCs into the skin, leading to a pDC-dependent reduced melanoma growth [73]. In another study, treatment of human basal cell carcinoma with imiquimod resulted in tumor regression by recruiting pDCs that specifically lysed the tumor cells expressing TRAIL receptor 1 in a TRAIL-dependent manner, and mDCs that expressed granzyme B [44]. The fact that pDCs only lysed cells expressing TRAILR1 indicates that these cells have the capacity to act as anticancer effector cells, thereby showing potential as targets for tumor clearance. These data suggest that tumor-infiltrating DCs can act as killer cells that are directly involved in tumor clearance. A recent study demonstrated that depletion of unactivated pDCs in an orthotopic mammary tumor model delayed tumor growth; however, in the same model, intratumoral administration of a TLR7 agonist led to pDC- and type-I-IFN-dependent tumor regression [74]. These findings point to a Janus-faced function of tumor infiltrating pDCs, and suggest that their function can be largely determined by context and activation state.

**Indirect antitumor activity of killer DCs via amplification of the adaptive immune response**

In the past decade, clinical trials carried out by investigators worldwide have shown that vaccination with DCs loaded ex vivo with tumor peptides can induce tumor-specific immune responses in patients with advanced cancer [75]. However, the clinical results obtained so far have been rather disappointing, with only a minority of the treated patients showing long-lasting clinical responses. Many research efforts are currently being undertaken to improve the clinical efficacy of DC-based cancer immunotherapy protocols. Thus far, virtually all clinical trials were based on ex vivo generated DCs, either derived from monocytes or CD34+ progenitor cells. Only recently, the possibility has been explored to exploit scarce naturally circulating DCs such as pDCs to vaccinate end-stage melanoma patients, which showed promising results in terms of overall survival [2].

Several research groups have demonstrated that human killer DCs, apart from their direct tumorcidal activity, can present tumor antigen to T cells, providing a strong rationale for the use of killer DCs in DC-based vaccination protocols. Both IL-15 and IFNα differentiated CD56+ MoDCs were found to be efficient stimulators of antigen-specific T cell responses [26,27]. Human pDCs also have the capacity to present antigens and be potent stimulators of both CD4+ and CD8+ T cell responses [2,50,76]. The high effector: target ratios that are required to detect killing activity argue in favor of a more predominant role for DCs in the acquisition and presentation of antigens rather than a role as effector cells capable of killing of tumor or virus-infected cells.

**Concluding remarks**

We have reviewed recent studies providing evidence for an effector role for DCs in cytolyis. We propose that DCs, and pDCs in particular, present a promising target for immunotherapy because they infiltrate tumor lesions and are, upon activation, capable of specifically kill tumor cells, either directly or via activation of other cytotoxic effector cells. However, many questions remain before killer DCs
can be used in their full capacity in a clinical situation. How exactly do killer DCs recognize tumor/target cells, and in particular MHC-class-I-negative cells? What are the exact mechanisms that these DCs use, for example, exclusively TRAIL or other mechanisms? Furthermore, can human killer DC cross-present antigens derived from their killed target cells? Answering these questions may help to exploit these killer DCs for immunotherapy.

Acknowledgments

This work was supported by The Netherlands Organization for Scientific Research (NWO ZonMW) (Vidi grant 9177863 to LMdV), the Netherlands Institute for Regenerative Medicine (NIRM, grant No. FES0908) and EU (ERC grant 269019). ES is a former postdoctoral research fellow of the Research Foundation Flanders (FWO Vlaanderen) and is supported by a training grant of the Belgian Hematological Society. SA is a former PhD fellow of the Research Foundation Flanders and currently holds an Emmanuel Van der Schueren Fellowship of the Flemish League against Cancer (Vlaamse Liga tegen Kanker). SA is also supported by a personal grant from the Belgian Foundation Against Cancer and the Belgian public utility foundation VOCATIO. CGF was awarded with the NWO Spinoza award.

References

1. Banchereau, J. and Steinman, R.M. (1998) Dendritic cells and the control of immunity. Nature 392, 245–252
2. Tel, J. et al. (2013) Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res. 73, 1063–1075
3. Shortman, K. et al. (1997) Dendritic cells and T lymphocytes: developmental and functional interactions. Ciba Found. Symp. 204, 130–138 discussion 138–141
4. Chan, C.W. et al. (2006) Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat. Med. 12, 207–213
5. Taieb, J. et al. (2006) A novel dendritic cell subset involved in tumor immunosurveillance. Nat. Med. 12, 214–219
6. Pillarsetty, V.G. et al. (2005) Natural killer dendritic cells have both antigen presenting and lytic function and in response to CpG produce IFN-gamma via autocrine IL-12. J. Immunol. 174, 2612–2618
7. Blasius, A.L. et al. (2007) Development and function of murine B220+CD11c+NK1.1+ cells identify them as a subset of NK cells. J. Exp. Med. 204, 2561–2568
8. Vosshenrich, C.A. et al. (2007) CD11cLoB220+ interferon-producing killer dendritic cells are activated natural killer cells. J. Exp. Med. 204, 2569–2578
9. Caminse, I. et al. (2007) Putative IKDCs are functionally and developmentally similar to natural killer cells, but not to dendritic cells. J. Exp. Med. 204, 2579–2590
10. Bonmort, M. et al. (2008) Killer dendritic cells: IKDC and the others. Curr. Opin. Immunol. 20, 558–565
11. Larmoner, N. et al. (2010) Killer dendritic cells and their potential for cancer immunotherapy. Cancer Immunol. Immunother. 59, 1–11
12. Griffith, T.S. et al. (1999) Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J. Exp. Med. 189, 1343–1354
13. Papewalis, C. et al. (2011) Increased numbers of tumor-lysing monocytes in cancer patients. Mol. Cell. Endocrinol. 337, 52–61
14. Sconochia, G. et al. (2005) Phenotype and function of a CD56+-peripheral blood monocyte. Leukemia 19, 69–76
15. Nakayama, M. et al. (2000) Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J. Exp. Med. 192, 1373–1380
16. Schmitz, M. et al. (2005) Tumoricidal potential of native blood dendritic cells: direct tumor cell killing and activation of NK cell-mediated cytotoxicity. J. Immunol. 174, 4127–4134
17. Schmitz, M. et al. (2002) Native human blood dendritic cells as potent effectors in antibody-dependent cellular cytotoxicity. Blood 100, 1502–1504
18. Vidalain, P.O. et al. (2000) Measles virus induces functional TRAIL production by human dendritic cells. J. Virol. 74, 556–559
19. Fugier-Vivier, I. et al. (1997) Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of dendritic and T cells. J. Exp. Med. 186, 813–823
20. Raferty, M.J. et al. (2001) Targeting the function of mature dendritic cells by human cytomegalovirus: a multilayered viral defense strategy. Immunity 15, 997–1009
21. Lichtner, M. et al. (2004) HIV type 1-infected dendritic cells induce apoptotic death in infected and uninfected primary CD4 T lymphocytes. AIDS Res. Hum. Retroviruses 20, 175–182
22. Quaranta, M.G. et al. (2004) HIV-1 Nef equips dendritic cells to reduce survival and function of CD4+ T cells: a mechanism of immune evasion. FASEB J. 18, 1459–1461
23. Majumder, B. et al. (2007) Dendritic cells infected with vpr-positive human immunodeficiency virus type 1 induce CD8+ T-cell apoptosis via upregulation of tumor necrosis factor alpha. J. Virol. 81, 7388–7389
24. Vidalain, P.O. et al. (2001) Cytotoxic activity of human dendritic cells is differentially regulated by double-stranded RNA and CD40 ligand. J. Immunol. 167, 3765–3772
25. Liu, S. et al. (2001) The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells. J. Immunol. 166, 5407–5415
26. Papewalis, C. et al. (2008) IFN-alpha skews monocytes into CD56+ expressing dendritic cells with potent functional activities in vitro and in vivo. J. Immunol. 180, 1462–1470
27. Anguille, S. et al. (2012) Interleukin-15-induced CD56+ myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential. PLoS ONE 7, e51851
28. Tomihara, K. et al. (2006) Gene transfer of CD40-ligand to dendritic cells stimulates interferon-gamma production to induce growth arrest and apoptosis of tumor cells. Gene Ther. 13, 203–213
29. Lu, G. et al. (2002) Innate direct anticancer effector function of human immature dendritic cells. II. Role ofTNF, lymphotoxin-alpha1beta2, Fas ligand, and TNF-related apoptosis-inducing ligand. J. Immunol. 168, 1831–1839
30. Joo, H.G. et al. (2002) Human dendritic cells induce tumor-specific apoptosis by soluble factors. Int. J. Cancer 102, 20–28
31. Yang, R. et al. (2001) Immature dendritic cells kill ovarian carcinoma cells by a FAS/FASL pathway, enabling them to sensitize tumor-specific CTLs. Int. J. Cancer 94, 407–413
32. Zhao, L. and Tyrrell, D.L. (2013) Myeloid dendritic cells can kill T cells during chronic hepatitis C virus infection. Virol. Immunol. 26, 25–39
33. Vanderheyde, N. et al. (2001) Tumoricidal activity of monocyte-derived dendritic cells: evidence for a caspase-8-dependent, Fas-associated death domain-independent mechanism. J. Immunol. 167, 3565–3569
34. Schultz, P.M. et al. (2007) Human allogeneic and murine xenogeneic dendritic cells are cytotoxic to human tumor cells via two distinct pathways. Cancer Biol. Ther. 6, 672–683
35. Vanderheyde, N. et al. (2004) Distinct mechanisms are involved in tumoristatic and tumoricidal activities of monocyte-derived dendritic cells. Immunol. Lett. 91, 99–101
36. Kim, S.K. et al. (2013) Enhanced anti-cancer activity of human dendritic cells sensitized with gamma-irradiation-induced apoptotic colon cancer cells. Cancer Lett. 335, 276–288
37. Sakko, L.V. et al. (2012) Cytotoxic activity of dendritic cells as a possible mechanism of negative regulation of T lymphocytes in pulmonary tuberculosis. Clin. Dev. Immunol. 2012, 628635
38. Cottrez, F. et al. (1997) Priming of human CD4+ antigen-specific T cells to undergo apoptosis by HIV-infected monocytes. A two-step mechanism involving the gp120 molecule. J. Clin. Invest. 99, 257–266
39. MacDonald, K.P. et al. (2002) Characterization of human blood dendritic cell subsets. Blood 100, 4512–4520
40. Fang, C. et al. (1999) Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Exp. Med. 190, 1155–1164
41. Janic, B.M. et al. (2002) Innate direct anticancer effector function of human immature dendritic cells. I. Involvement of an apoptosis-inducing pathway. J. Immunol. 168, 1823–1830
42. Ciesek, S. et al. (2008) Impaired TRAIL-dependent cytotoxicity of CD1c-positive dendritic cells in chronic hepatitis C virus infection. J. Virol. Hepat. 15, 200–211
43. Hemont, C. et al. (2013) Human blood mDC subsets exhibit distinct TLR repertoire and responsiveness. J. Leukoc. Biol. 93, 599–609
Stary, G. et al. (2007) Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J. Exp. Med. 204, 1441–1451

Manna, P.P. et al. (2013) IL-15 activated human peripheral blood dendritic cell kill allogeneic and xenogeneic endothelial cells via apoptosis. Cytokine 61, 118–126

Dziolek, A. et al. (2000) BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J. Immunol. 165, 6037–6046

Cella, M. et al. (1999) Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 5, 919–925

Karthaus, N. et al. (2012) Deciphering the message broadcast by tumor-infiltrating dendritic cells. Am. J. Pathol. 181, 733–742

Chaperot, L. et al. (2006) Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J. Immunol. 176, 248–255

Tel, J. et al. (2012) Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood 120, 3936–3944

Kahl, M.L. et al. (2012) TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-alpha-mediated antitumor reactivity. J. Immunol. 188, 1583–1591

Matsui, T. et al. (2009) CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J. Immunol. 182, 6815–6823

Bratke, K. et al. (2010) Functional expression of granzyme B in human plasmacytoid dendritic cells: a role in allergic inflammation. Clin. Exp. Allergy 40, 1015–1024

Jahrsdorfer, B. et al. (2010) Granzyyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion. Blood 115, 1156–1165

Colisson, R. et al. (2010) Free HTLV-1 induces TRAIL-dependent innate immune response and TRAIL relocation in killer plasmacytoid dendritic cells. Blood 115, 2177–2185

Hardy, A.W. et al. (2007) HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-alpha. Proc. Natl. Acad. Sci. U.S.A. 104, 17453–17458

Barblu, L. et al. (2012) Plasmacytoid dendritic cells (pDCs) from HIV controllers produce interferon-alpha and differentiate into functional killer pDCs under HIV activation. J. Infect. Dis. 206, 790–801

Chehimi, J. et al. (2010) Inability of plasmacytoid dendritic cells to directly lyse HIV-infected autologous CD4+ T cells despite induction of tumor necrosis factor-related apoptosis-inducing ligand. J. Virol. 84, 2769–2773

Vlichek, J. (2003) Boosting p53 with interferon and viruses. Nat. Immunol. 4, 825–826

Arico, E. and Belardelli, F. (2012) Interferon-alpha as antiviral and antitumor vaccine adjuvants: mechanisms of action and response signature. J. Interferon Cytokine Res. 32, 235–247

Anguille, S. et al. (2011) Interferon-alpha in acute myeloid leukemia: an old drug revisited. Leukemia 25, 739–748

Diamond, M.S. et al. (2011) Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208, 1989–2003

Spadaro, F. et al. (2012) IFN-alpha enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood 119, 1407–1417

Fuertes, M.B. et al. (2011) Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8(+)alpha+ dendritic cells. J. Exp. Med. 208, 2005–2016

Nguyen, K.B. et al. (2002) Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J. Immunol. 169, 4279–4287

Kemp, T.J. et al. (2003) Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation. J. Immunol. 171, 212–218

Kayagaki, N. et al. (1999) Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189, 1451–1460

Chawla-Sarkar, M. et al. (2003) Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8, 237–249

Herbeujal, J.P. et al. (2005) Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 102, 13974–13979

Trelleix, I. et al. (2004) Dendritic cell infiltration and prognosis of early stage breast cancer. Clin. Cancer Res. 10, 7466–7474

Labidi-Galy, S.I. et al. (2011) Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res. 71, 5423–5434

Tabarkiewicz, J. et al. (2008) CD1e+ and CD303+ dendritic cells in peripheral blood, lymph nodes and tumor tissue of patients with non-small cell lung cancer. Oncol. Rep. 19, 237–243

Drobits, B. et al. (2012) Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J. Clin. Invest. 122, 575–585

Le Mercier, I. et al. (2013) Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TRIL7 ligand treatment. Cancer Res. 73, 4629–4640

Fidgior, C.G. et al. (2004) Dendritic cell immunotherapy: mapping the way. Nat. Med. 10, 475–480

Tel, J. et al. (2013) Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag-stake than myeloid dendritic cell subsets. Blood 121, 459–467

Jahnisch, H. et al. (2013) TRIL7/8 agonists trigger immunostimulatory properties of human 6-sulf-α-N-acetyl-dendritic cells. Cancer Lett. 335, 119–127

Chapoval, A.I. et al. (2000) In vitro growth inhibition of a broad spectrum of tumor cell lines by activated human dendritic cells. Blood 95, 2346–2351

Hubeit, P. et al. (2001) Dendritic cells induce the death of human papillomavirus-transformed keratinocytes. FASEB J. 15, 2521–2523

Shi, J. et al. (2005) Activated human umbilical cord blood dendritic cells kill tumor cells without damaging normal hematological progenitor cells. Cancer Sci. 96, 127–133

Korthals, M. et al. (2007) Monocyte derived dendritic cells generated by IFN-alpha acquire mature dendritic and natural killer cell properties as shown by gene expression analysis. J. Transl. Med. 5, 46

Hill, K.S. et al. (2008) OK432-activated human dendritic cells kill tumor cells via CD40/CD40 ligand interactions. J. Immunol. 181, 3108–3115

Shibru, D. et al. (2008) Does the 3-gene diagnostic assay accurately distinguish benign from malignant thyroid neoplasms? Cancer 113, 930–935

Law, H.K. et al. (2009) Toll-like receptors, chemokine receptors and death receptor ligands responses in SARS coronavirus infected human monocyte derived dendritic cells. BMC Immunol. 10, 35

Jung, S.T. et al. (2010) Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRIIb potentiate tumor cell killing by monocyte-dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 107, 604–609

Lakomy, D. et al. (2011) Cytotoxic dendritic cells generated from cancer patients. J. Immunol. 187, 2775–2782

Koski, G.K. et al. (2012) A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J. Immunother. 35, 54–65

Manna, P.P. and Mohananukumar, T. (2002) Human dendritic cell mediated cytotoxicity against breast carcinoma cells in vitro. J. Leukoc. Biol. 72, 312–320

Stary, G. et al. (2009) Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients. Blood 114, 3854–3863

Riboldi, E. et al. (2009) Engagement of BDCA-2 blocks TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. Immunobiology 214, 685–876